Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAR 440340

Drug Profile

SAR 440340

Alternative Names: REGN-3500; SAR440340

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals; Sanofi
  • Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin-33 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease
  • No development reported Inflammation

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in Belgium (IV)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in Belgium (SC)
  • 07 Aug 2019 Sanofi completes a phase II trial in Asthma in USA, Ukraine, Turkey, Russia, Poland, Mexico, Chile and Argentina (NCT03387852)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top